Preclinical Pharmacodynamics of Antihypertensives

  • Robert A. Branch
  • Edwin K. Jackson


The objective of research in the antihypertensive area, and therefore the objective of preclinical studies with potential antihypertensive drugs, is to identify therapeutic entities with: increased efficacy, decreased toxicity, increased ease and convenience of administration, an improved profile on metabolic, hemodynamic and cellular parameters, and defined and unique mechanisms of action.


Arterial Blood Pressure Antihypertensive Drug Renin Inhibitor Organ Blood Flow Experimental Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, M. A., A. Bobik, and P. I. Korner (1990). Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension 16, 252–260.PubMedCrossRefGoogle Scholar
  2. Anderson, S., H. G. Rennke, and B. M. Brenner (1986). Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J. Clin. Invest.,77, 1993–2000.PubMedCrossRefGoogle Scholar
  3. Antonaccio, M. J., B. Rubin, Z. P. Horovitz, R. J. Laffoa, M. E. Goldberg, J. P. High, D. N. Harris, and I. Zaidi (1979). Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I- converting enzyme, in spontaneously hypertensive rats. Japan J. Pharmacol.,29, 285–294.CrossRefGoogle Scholar
  4. Antonaccio, M. J., J. High, J. M. Deforrest, and E. Sybertz (1986). Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: Relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. J. Pharmacol. Exp. Ther., 238 378–387.PubMedGoogle Scholar
  5. Bouhnik, J., F. X. Galen, J. Menard, P. Corvol, R. Seyer, J. A. Fehrentz, D. Le N’Guyen, P. Falorand, and B. Castro (1987). Production and characterization of human renin antibodies with region-oriented synthetic peptides. J. Biol. Chem., 262: 2913–2918.PubMedGoogle Scholar
  6. Buhler, F. R., J. H. Laragh, L. Baer, E. D. Vaughan, and H. R. Brunner (1972). Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renindependent hypertensive diseases. N. Engl. J. Med., 287 1209–1214.PubMedCrossRefGoogle Scholar
  7. Gulati, O. P., and J. F. Liard (1979). Effects of propranolol in chronic two-kidney goldblatt hypertension in rats. Arch. Int. Pharmacodyn., 240 285–293.PubMedGoogle Scholar
  8. Guyton, A. C. (1990) Personal and historical perspectives: The surprising kidney-fluid mechanism for pressure control - its infinite gain! Hypertension 16, 725–730.Google Scholar
  9. Haber, E., and K. Y. Hui (1990). Specific renin inhibitors: The concept and the prospects. In J. H. Laragh, and B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 2343–2350.Google Scholar
  10. Jackson, E. K. (1992). In vivo evaluation of the antagonist activity of angiotensin I analogs. J. Pharmacol. Exp. Ther.,260, 223–231.PubMedGoogle Scholar
  11. Koike, H., K. Ito, M. Miyamoto, and H. Nishino (1980). Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 2, 299–303.Google Scholar
  12. Laragh, J. H. (1978). The renin system in high blood pressure, from disbelief to reality: converting-enzyme blockade for analysis and treatment. Progress in Cardiovascular Diseases 21, 159–166.Google Scholar
  13. Maxwell, M. H. (1988). Beyond blood pressure control: effect of antihypertensive therapy on cardiovascular risk factors. Am. J. Hyper.,1, 366S–371S.Google Scholar
  14. McGiff, J. C., and C. P. Quilley (1981). Controversies in cardiovascular research: the rat with spontaneous genetic hypertension is not a suitable model of human essential hypertension. Circ. Res.,48, 455–463.PubMedCrossRefGoogle Scholar
  15. Schwartz, S. M., M. W. Majesky, and R. J. Dilley (1990). Vascular remodeling in hypertension and atherosclerosis. In J. H. Laragh, B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 521–539.Google Scholar
  16. Stamler, J. (Comments by), and T. Kotchen (Session Chairman) (1991). Panel Discussion: Session VII. Research and Public Health Directions: Public Health and Clinical Perspectives: Is salt restriction for everyone? Hypertension 17 (Suppl I), I-216-I-221.Google Scholar
  17. Sweet, C. S., P. T. Arbegast, L. S. Gaul, E. H. Blaine, and D. M. Gross (1981). Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Eur. J. Pharmacol., 76: 167–176.PubMedCrossRefGoogle Scholar
  18. Timmermans, P. B. M. W. M., D. J. Carini, A. T. Chiu, J. V. Duncia, W. A. Price, G. J. Wells, P. C. Wong, R. R. Wexler, and A. L. Johnson (1990). The discovery and physiological effects of a new class of highly specific angiotensin II-receptor antagonists. In J. H. Laragh and B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 2351–2360.Google Scholar
  19. Tolins, J. P., and L. Raij (1990). Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16, 452–461.Google Scholar
  20. Trippodo, N. C., and E. D. Frohlich (1981). Controversies in cardiovascular research: Similarities of genetic (spontaneous) hypertension: Man and rat. Circ. Res.,48, 309–319.PubMedCrossRefGoogle Scholar
  21. Weinberger, M. H. (1990). Clinical Conference: Optimizing cardiovascular risk reduction during antihypertensive therapy. Hypertension 16, 201–211.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Robert A. Branch
    • 1
  • Edwin K. Jackson
    • 1
  1. 1.Center for Clinical PharmacologyUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations